Overview

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.
Phase:
Phase 1
Details
Lead Sponsor:
Trevena Inc.
Treatments:
Moxifloxacin